Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Современные гормональные контрацептивы и масса тела
Современные гормональные контрацептивы и масса тела
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Kopelman P, Stock M. Clinical Obesity, 1998.
2. Bjorkelund C et al. Reproductive history in relation to relative weight and fat distribution. Int J Obes 1996; 20 (3): 213–9.
3. Samsioe G. Oral contraceptives and the cardiovascular issue. In: The Pill; Parthenon Publishing Group; London; 1990; 43–5.
4. Fortney J, Harper J. Oral contraceptives and expectancy. Stud Fam Planning 1986; 17: 117–25.
5. Rosenberg M. Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower- dose oral contraceptives: a randomized trial of 20 microgram and 35 microgram preparations. Contraception 1999; 6: 321–9.
6. Phillips N, Duffy T. One hour glucose tolerance in relation to use of oral contraceptive drugs. Am J Obst Gyn 1973; 116: 91–100.
7. Risser WL, Gefter LR. Weight change in adolescents who used hormonal contraception. J Adolesc Health 1999; 24 (6): 433–6.
8. Rosenbaum H. Resent developments in the composition of oral contraceptives. In: The Pill; Parthenon Publishing Group; London; 1990; 53–9.
9. Moses LE. The influence of a secvential oral contraceptiveon the carbohydrate metabolism. Boston; Exc Medical International Congress Series 224, 1970.
10. Goldzieher JW, Fotherb KY. Pharmacology of the Contraceptive Steroids. Raven Press, New York, 1994; 354–7.
11. Berga SL. Metabolic and endocrine effect of the desogestrel-containing oral contraceptive Mircette. Am J Obst Gyn 1998; 179 (1): S9–17.
12. van der Mooren MJ, Klipping CA. comparative study of the effect of gestodene 60 mcg/EE 15 mcg.and desogestrel 150 mcg/EE 20 mcg on hemostatic balance, blod lipid levels and carbohydrate metabolism. Eur J Contracept Reprod Health Care. 1999; 4 (Suppl. 2): 27–35.
13. Eck LH, Bennet AG. Differenctes in macronutrient selections in users and nonusers an oral contraceptive. Am J Clin Nutr 1997; 65 (2): 419–24.
14. Litchfield RE, Grunvald KK. Oral contraceptives and fat patterning in young adult women. Hum Biol 1988; 60 (5): 793–800.
15. van den Heuvel MW et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005; 72: 168–74
16. Guillbaud J. Contraception. Churchhill Livingstone; London; 1993; 156–268.
17. Gallo MF et al. Combination estrogen-progestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet Gynecol 2004; 103 (2): 359–73.
18. Lammers P, Op ten Berg M. Phase III Clinical trial with a new oral contraceptive containing 150 mcg desogestrel and 20 mcg ethynilestradiol. ACT Obstetr Gynecol Scand 1991; 70: 497–500.
19. Lavín et al. Effect on bleeding patterns following the use of a low dose desogestrel-containing oral contraceptive. Eur J Contracept Reprod Health Care 2002; 7 (suppl. 1): 86.
20. Milsom I et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 mg ethinylestradiol and 3 mg drospirenone. Human Reproduction 2006; 21 (9): 2304–11.
21. Keam SJ, Wagstaff AJ. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive. Treat Endocrinol 2003; 2: 49–70.
2. Bjorkelund C et al. Reproductive history in relation to relative weight and fat distribution. Int J Obes 1996; 20 (3): 213–9.
3. Samsioe G. Oral contraceptives and the cardiovascular issue. In: The Pill; Parthenon Publishing Group; London; 1990; 43–5.
4. Fortney J, Harper J. Oral contraceptives and expectancy. Stud Fam Planning 1986; 17: 117–25.
5. Rosenberg M. Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower- dose oral contraceptives: a randomized trial of 20 microgram and 35 microgram preparations. Contraception 1999; 6: 321–9.
6. Phillips N, Duffy T. One hour glucose tolerance in relation to use of oral contraceptive drugs. Am J Obst Gyn 1973; 116: 91–100.
7. Risser WL, Gefter LR. Weight change in adolescents who used hormonal contraception. J Adolesc Health 1999; 24 (6): 433–6.
8. Rosenbaum H. Resent developments in the composition of oral contraceptives. In: The Pill; Parthenon Publishing Group; London; 1990; 53–9.
9. Moses LE. The influence of a secvential oral contraceptiveon the carbohydrate metabolism. Boston; Exc Medical International Congress Series 224, 1970.
10. Goldzieher JW, Fotherb KY. Pharmacology of the Contraceptive Steroids. Raven Press, New York, 1994; 354–7.
11. Berga SL. Metabolic and endocrine effect of the desogestrel-containing oral contraceptive Mircette. Am J Obst Gyn 1998; 179 (1): S9–17.
12. van der Mooren MJ, Klipping CA. comparative study of the effect of gestodene 60 mcg/EE 15 mcg.and desogestrel 150 mcg/EE 20 mcg on hemostatic balance, blod lipid levels and carbohydrate metabolism. Eur J Contracept Reprod Health Care. 1999; 4 (Suppl. 2): 27–35.
13. Eck LH, Bennet AG. Differenctes in macronutrient selections in users and nonusers an oral contraceptive. Am J Clin Nutr 1997; 65 (2): 419–24.
14. Litchfield RE, Grunvald KK. Oral contraceptives and fat patterning in young adult women. Hum Biol 1988; 60 (5): 793–800.
15. van den Heuvel MW et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005; 72: 168–74
16. Guillbaud J. Contraception. Churchhill Livingstone; London; 1993; 156–268.
17. Gallo MF et al. Combination estrogen-progestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet Gynecol 2004; 103 (2): 359–73.
18. Lammers P, Op ten Berg M. Phase III Clinical trial with a new oral contraceptive containing 150 mcg desogestrel and 20 mcg ethynilestradiol. ACT Obstetr Gynecol Scand 1991; 70: 497–500.
19. Lavín et al. Effect on bleeding patterns following the use of a low dose desogestrel-containing oral contraceptive. Eur J Contracept Reprod Health Care 2002; 7 (suppl. 1): 86.
20. Milsom I et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 mg ethinylestradiol and 3 mg drospirenone. Human Reproduction 2006; 21 (9): 2304–11.
21. Keam SJ, Wagstaff AJ. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive. Treat Endocrinol 2003; 2: 49–70.
2. Bjorkelund C et al. Reproductive history in relation to relative weight and fat distribution. Int J Obes 1996; 20 (3): 213–9.
3. Samsioe G. Oral contraceptives and the cardiovascular issue. In: The Pill; Parthenon Publishing Group; London; 1990; 43–5.
4. Fortney J, Harper J. Oral contraceptives and expectancy. Stud Fam Planning 1986; 17: 117–25.
5. Rosenberg M. Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower- dose oral contraceptives: a randomized trial of 20 microgram and 35 microgram preparations. Contraception 1999; 6: 321–9.
6. Phillips N, Duffy T. One hour glucose tolerance in relation to use of oral contraceptive drugs. Am J Obst Gyn 1973; 116: 91–100.
7. Risser WL, Gefter LR. Weight change in adolescents who used hormonal contraception. J Adolesc Health 1999; 24 (6): 433–6.
8. Rosenbaum H. Resent developments in the composition of oral contraceptives. In: The Pill; Parthenon Publishing Group; London; 1990; 53–9.
9. Moses LE. The influence of a secvential oral contraceptiveon the carbohydrate metabolism. Boston; Exc Medical International Congress Series 224, 1970.
10. Goldzieher JW, Fotherb KY. Pharmacology of the Contraceptive Steroids. Raven Press, New York, 1994; 354–7.
11. Berga SL. Metabolic and endocrine effect of the desogestrel-containing oral contraceptive Mircette. Am J Obst Gyn 1998; 179 (1): S9–17.
12. van der Mooren MJ, Klipping CA. comparative study of the effect of gestodene 60 mcg/EE 15 mcg.and desogestrel 150 mcg/EE 20 mcg on hemostatic balance, blod lipid levels and carbohydrate metabolism. Eur J Contracept Reprod Health Care. 1999; 4 (Suppl. 2): 27–35.
13. Eck LH, Bennet AG. Differenctes in macronutrient selections in users and nonusers an oral contraceptive. Am J Clin Nutr 1997; 65 (2): 419–24.
14. Litchfield RE, Grunvald KK. Oral contraceptives and fat patterning in young adult women. Hum Biol 1988; 60 (5): 793–800.
15. van den Heuvel MW et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005; 72: 168–74
16. Guillbaud J. Contraception. Churchhill Livingstone; London; 1993; 156–268.
17. Gallo MF et al. Combination estrogen-progestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet Gynecol 2004; 103 (2): 359–73.
18. Lammers P, Op ten Berg M. Phase III Clinical trial with a new oral contraceptive containing 150 mcg desogestrel and 20 mcg ethynilestradiol. ACT Obstetr Gynecol Scand 1991; 70: 497–500.
19. Lavín et al. Effect on bleeding patterns following the use of a low dose desogestrel-containing oral contraceptive. Eur J Contracept Reprod Health Care 2002; 7 (suppl. 1): 86.
20. Milsom I et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 mg ethinylestradiol and 3 mg drospirenone. Human Reproduction 2006; 21 (9): 2304–11.
21. Keam SJ, Wagstaff AJ. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive. Treat Endocrinol 2003; 2: 49–70.
________________________________________________
2. Bjorkelund C et al. Reproductive history in relation to relative weight and fat distribution. Int J Obes 1996; 20 (3): 213–9.
3. Samsioe G. Oral contraceptives and the cardiovascular issue. In: The Pill; Parthenon Publishing Group; London; 1990; 43–5.
4. Fortney J, Harper J. Oral contraceptives and expectancy. Stud Fam Planning 1986; 17: 117–25.
5. Rosenberg M. Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower- dose oral contraceptives: a randomized trial of 20 microgram and 35 microgram preparations. Contraception 1999; 6: 321–9.
6. Phillips N, Duffy T. One hour glucose tolerance in relation to use of oral contraceptive drugs. Am J Obst Gyn 1973; 116: 91–100.
7. Risser WL, Gefter LR. Weight change in adolescents who used hormonal contraception. J Adolesc Health 1999; 24 (6): 433–6.
8. Rosenbaum H. Resent developments in the composition of oral contraceptives. In: The Pill; Parthenon Publishing Group; London; 1990; 53–9.
9. Moses LE. The influence of a secvential oral contraceptiveon the carbohydrate metabolism. Boston; Exc Medical International Congress Series 224, 1970.
10. Goldzieher JW, Fotherb KY. Pharmacology of the Contraceptive Steroids. Raven Press, New York, 1994; 354–7.
11. Berga SL. Metabolic and endocrine effect of the desogestrel-containing oral contraceptive Mircette. Am J Obst Gyn 1998; 179 (1): S9–17.
12. van der Mooren MJ, Klipping CA. comparative study of the effect of gestodene 60 mcg/EE 15 mcg.and desogestrel 150 mcg/EE 20 mcg on hemostatic balance, blod lipid levels and carbohydrate metabolism. Eur J Contracept Reprod Health Care. 1999; 4 (Suppl. 2): 27–35.
13. Eck LH, Bennet AG. Differenctes in macronutrient selections in users and nonusers an oral contraceptive. Am J Clin Nutr 1997; 65 (2): 419–24.
14. Litchfield RE, Grunvald KK. Oral contraceptives and fat patterning in young adult women. Hum Biol 1988; 60 (5): 793–800.
15. van den Heuvel MW et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005; 72: 168–74
16. Guillbaud J. Contraception. Churchhill Livingstone; London; 1993; 156–268.
17. Gallo MF et al. Combination estrogen-progestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet Gynecol 2004; 103 (2): 359–73.
18. Lammers P, Op ten Berg M. Phase III Clinical trial with a new oral contraceptive containing 150 mcg desogestrel and 20 mcg ethynilestradiol. ACT Obstetr Gynecol Scand 1991; 70: 497–500.
19. Lavín et al. Effect on bleeding patterns following the use of a low dose desogestrel-containing oral contraceptive. Eur J Contracept Reprod Health Care 2002; 7 (suppl. 1): 86.
20. Milsom I et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 mg ethinylestradiol and 3 mg drospirenone. Human Reproduction 2006; 21 (9): 2304–11.
21. Keam SJ, Wagstaff AJ. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive. Treat Endocrinol 2003; 2: 49–70.
Авторы
Ю.Э.Доброхотова
Кафедра акушерства и гинекологии московского факультета с курсом ФУВ РГМУ
Кафедра акушерства и гинекологии московского факультета с курсом ФУВ РГМУ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.